Spring Bank to Present at the Cantor Fitzgerald Global Healthcare Conference
HOPKINTON, Mass., Sept. 13, 2017 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of viral infections, inflammatory diseases and certain cancers, today announced that Martin J. Driscoll, Chairman, President, and Chief Executive Officer, will present a corporate overview at the Cantor Fitzgerald Global Healthcare Conference being held in New York CitySeptember 25-27, 2017.
Presentation Details: Date: Monday, September 25 Time: 9:10am Eastern Time Location: InterContinental New York Barclay Hotel, Empire Ballroom 2 - Track 3
About Spring Bank
Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. The company is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases, including hepatitis B virus (HBV) and other SMNH product candidates, including SB 11285, the Company’s lead immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of INterferon Genes, or STING, pathway.
For investor inquiries: Spring Bank Pharmaceuticals, Inc. Jonathan Freve Chief Financial Officer (508) 473-5993